Eravacycline Dihydrochloride Patent Expiration
Eravacycline Dihydrochloride is Used for treating complicated intra-abdominal infections in adults aged 18 years and older. It was first introduced by Tetraphase Pharmaceuticals Inc
Eravacycline Dihydrochloride Patents
Given below is the list of patents protecting Eravacycline Dihydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xerava | US10961190 | Crystalline forms of eravacycline | Oct 19, 2037 | Tetraphase Pharms |
| Xerava | US11578044 | Crystalline forms of eravacycline | Oct 19, 2037 | Tetraphase Pharms |
| Xerava | US8906887 | C7-fluoro substituted tetracycline compounds | Dec 28, 2030 | Tetraphase Pharms |
| Xerava | US8796245 | C7-fluoro substituted tetracycline compounds | Aug 07, 2029 | Tetraphase Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Eravacycline Dihydrochloride's patents.
Latest Legal Activities on Eravacycline Dihydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Eravacycline Dihydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8906887 |
| transaction for FDA Determination of Regulatory Review Period | 23 Feb, 2024 | US8906887 |
| Recordation of Patent Grant Mailed Critical | 14 Feb, 2023 | US11578044 |
| Patent Issue Date Used in PTA Calculation Critical | 14 Feb, 2023 | US11578044 |
| Email Notification Critical | 26 Jan, 2023 | US11578044 |
| Issue Notification Mailed Critical | 25 Jan, 2023 | US11578044 |
| Application Is Considered Ready for Issue Critical | 09 Jan, 2023 | US11578044 |
| Dispatch to FDC | 09 Jan, 2023 | US11578044 |
| Supplemental Papers - Oath or Declaration | 05 Jan, 2023 | US11578044 |
| Issue Fee Payment Verified Critical | 05 Jan, 2023 | US11578044 |
Eravacycline Dihydrochloride's Family Patents
